Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240006/S018

Varipulse Bi-Directional Catheter

Biosense Webster, Inc. · Decision date Nov 3, 2026

FDA DECISIONP240006/S018

What did the FDA approve?

FDA records P240006/S018 as a supplement to PMA P240006, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 3, 2026.

FDA approval order statement

extension of the product shelf-life from one (1) year to three (3) years
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Nov 3, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P240006/S018
Regulatory pathway
PMA supplement
Product code
QZI
Decision code
APPR
Decision date
Nov 3, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Product code
QZI
FDA device class
3

For the original device and its historical approval scope, see PMA P240006. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240006 · Original PMA

    VARIPULSE Platform (VARIPULSE Catheter; TRUPULSE Generator; Sterile Interface Cable; nGEN Pump)

  2. P240006/S018 received

    Application receipt date recorded by FDA.

  3. P240006/S019 · Related supplement

    VARIPULSE Platform (VARIPULSE Catheter; TRUPULSE Generator; Sterile Interface Cable; nGEN Pump)

  4. P240006/S020 · Related supplement

    VARIPULSE BI-DIRECTIONAL CATHETER

  5. P240006/S018 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P240006. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240006

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Kardium, Inc.PMA supplementOct 27, 2026FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biosense Webster, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
31 Technology Dr., Suite 200, Irvine, CA, 91618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records